• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Trade Desk (TTD) Following OpenPath Healthcare Tie Up Is The Stock Now A Bargain

    Simply Wall St·09/27/2026 02:21:10
    語音播報

    Why Trade Desk Stock Is Back In Focus

    OptimizeRx’s new integration with OpenPath, Trade Desk (TTD)’s supply path optimization tool, has thrown fresh attention on the stock as investors reassess the company’s role in healthcare-focused digital advertising.

    Trade Desk’s new healthcare integrations are landing against a weak tape, with the 7-day share price return down 9.48% and the 90-day share price return down 32.44%, while the 1-year total shareholder return has fallen 73.27%. This points to fading momentum as investors reassess both growth potential and risk.

    Scan other ad tech and healthcare-focused platforms that may be better aligned with your risk tolerance by reviewing the hand-picked 32 high quality undervalued stocks now that Trade Desk is back in the spotlight.

    Trade Desk now trades far below its recent highs while new healthcare deals are just hitting the tape. Is most of the rerating already gone, or does today’s valuation still leave meaningful upside on the table?

    Most Popular Narrative: 57% Undervalued

    Against a last close of $12.60, the most followed narrative on Trade Desk pegs fair value at $29.24. This frames the current weakness as a deep discount rather than a minor pullback.

    Basically this is a stock that has bottomed out and has seen significant increased competition and resourcing challenges. Unless we see significant partnership and new endeavours I can’t see anything that will increase its growth outside of rapidly expanding global marketplace endeavours at 82% of revenue comes from the US.

    See why 23 investors see Trade Desk as 57% undervalued.

    Result: Fair Value of $29.24 (UNDERVALUED)

    Still, rising competition from Alphabet, Meta and Amazon, along with slowing revenue and net income growth, could quickly weaken the underpriced Trade Desk narrative.

    Find out about the key risks to this Trade Desk narrative.

    Next Steps

    Mixed signals around Trade Desk and its healthcare push can feel confusing, so move quickly, review the underlying data, and come to your own view by weighing the 1 key reward and 1 important warning sign.

    Looking For More Investment Ideas Beyond Trade Desk?

    If Trade Desk has your attention, do not stop here. Use fresh ideas from different corners of the market to pressure test and upgrade your overall portfolio.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.